A recent clinical study found increased plasma syndecan-1 in patients with AML compared with healthy controls; however, it did not find differences in circulating syndecan-1 between patients achieving remission and those failing to achieve remission following chemotherapy. The gene discussed is SDC1; the disease is acute myeloid leukemia.